ArticleDiscover oncology2026
A SEER derived prognostic nomogram identifies stage IV metastatic lung squamous cell carcinoma patients who may benefit from primary tumor resection.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesPrimary tumor resection has been associated with potential enhanced survival in select patients with stage IV metastatic lung squamous cell carcinoma (mLUSCC). However, identifying suitable candidates for surgery remains challenging. This study aimed to develop and validate a prognostic model to select mLUSCC patients likely to benefit from primary tumor resection.
methodsData on stage IV mLUSCC patients were retrieved from the SEER database. Patients were divided into surgery and nonsurgery groups based on primary tumor resection. Propensity score matching (PSM) using covariates including age, T/N stage, grade, metastases, chemotherapy, and others mitigated selection bias. Survival was assessed using Kaplan-Meier curves and Cox proportional hazards models. The surgery group was split randomly (70:30) into training and validation cohorts for model development via multivariate Cox regression.
resultsAmong 18,701 eligible patients, 3.57% (n = 668) underwent primary tumor resection. Post-PSM, median overall survival (mOS) was superior in the surgery group (11 [95% CI: 9–12] vs. 6 [5–6] months; P < 0.0001). The model demonstrated good discriminative ability, with AUCs for 6-, 9-, and 12-month survival of 0.799, 0.746, and 0.744 in the training cohort, and 0.708, 0.727, and 0.667 in the validation cohort. Calibration plots showed excellent agreement between predicted and observed probabilities.
conclusionsThis internally validated prognostic nomogram aims to identify patients with stage IV metastatic lung squamous cell carcinoma who are most likely to benefit from primary tumor resection, thereby supporting individualized multidisciplinary decision-making. Further external and prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.